Elicera Therapeutics
1.75
SEK
-1.96 %
ELIC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-1.96%
-10.94%
+14.38%
-22.57%
+75.35%
-61.62%
-61.54%
-70.44%
-
-71.77%
www.elicera.com/investors
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ELIC
Daily low / high price
1.74 / 1.835
SEK
Market cap
61.41M SEK
Turnover
178.52K SEK
Volume
101K
Latest videos
Financial calendar
Interim report
2024-11-28
Annual report
2025-02-13
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Di Yu | 9.8 % | 9.8 % |
| Magnus Essand | 9.6 % | 9.6 % |
| Jamal El-Mosleh | 8.4 % | 8.4 % |
| NOWO Global | 4.4 % | 4.4 % |
| Nordnet | 3.4 % | 3.4 % |
| Tuvedalen Ltd | 3.4 % | 3.4 % |
| Avanza | 3.3 % | 3.3 % |
| Göran Persson | 2.8 % | 2.8 % |
| Six Sis AG | 2.1 % | 2.1 % |
| Kaj Rintala | 1.4 % | 1.4 % |
ShowingAll content types
Elicera Therapeutics: BioStock: Elicera's CEO: "One of the biggest milestones in our history"
Elicera Therapeutics includes the first patient in the Phase I/II clinical study CARMA targeting B-cell lymphoma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools